Aromatase Inhibitors and Bone Health in Women With Breast Cancer-Reference-Cited by-同舟云学术

Aromatase Inhibitors and Bone Health in Women With Breast Cancer

Published:2006-11-20 Issue:33 Volume:24 Page:5305-5312
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Chien Amy Jo¹,Goss Paul E.¹

Affiliation:

1. From the Department of Internal Medicine, Massachusetts General Hospital; and Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.07.5382

Reference77 articles.

1. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

2. Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

3. Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group

4. Melton LJ III: How many women have osteoporosis now? J Bone Miner Res 10: 175,1995 -177,

5. Kanis JA: Bone and cancer: Pathophysiology and treatment of metastases. Bone 17: 101S,1995 -105S,

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL;Journal of Bone and Mineral Metabolism;2024-08-13

2. Aromatase inhibitors and fracture prevention – do 2017 guidelines work in real world?;BJC Reports;2024-05-01

3. Aromatase inhibitors and fracture prevention – do 2017 guidelines work in real world?;2023-06-28

4. Review of bone health in women with estrogen receptor–positive breast cancer receiving endocrine therapy;Women's Health;2023-01

5. Non-GCs Drug-Induced Osteoporosis;Biomechanical and Mechanobiological Analysis of Bone Mineral Density [Working Title];2022-10-27